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1. Introduction
Positron emission tomography (PET) is a non-invasive 
molecular imaging tool that provides tomographic 
images and quantitative parameters of perfusion, 
cell viability, proliferation and/or metabolic activity 
of tissues. These images result from the use of different substances 
of biological interest (sugars, amino acids, metabolic precursors, 
hormones) labelled with positron-emitting radionuclides (PET 
radiopharmaceuticals). Fusion of the aforementioned important 
functional information with the morphological detail provided 
by computed tomography (CT) as PET/CT provides clinicians 
with a sensitive and accurate one-step whole-body diagnostic and 
prognostic tool, which directs and changes patient management.
Several studies have demonstrated the superiority of combined 
PET/CT over either modality alone, and for many indications this is 
generally accepted as the gold standard for imaging in oncology. [1] 
The value of PET/CT imaging has been best demonstrated in the 
setting of oncology with the use of 18F-fluorodeoxyglucose (18F-
FDG). FDG is an analogue of glucose and is taken up by cells 
via the first stages of the normal glucose pathway and trapped 
inside cells with high glycolytic activity. Tumour uptake therefore 
correlates with tumour growth and viability, providing metabolic 
quantification and frequently useful information regarding 
tumour characterisation, patient prognosis and monitoring of 
the therapeutic response. Evidence is also rapidly accumulating 
for many indications in the fields of cardiology, neurology and 
infection imaging with existing tracers, and future growth is 
expected, given the numerous possibilities created by new tracers.
The rapid growth in PET/CT imaging worldwide, with the 
continual evolution of technology and clinical indications, makes 
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These recommendations are intended to serve an important and relevant role in advising referring physicians on the appropriate use 
of 18F-fluorodeoxyglucose (18F-FDG) and non-18F-FDG positron emission tomography/computed tomography (PET/CT), which can 
be a powerful tool in patient management in oncology, cardiology, neurology and infection/inflammation. PET is a non-invasive 
molecular imaging tool that provides tomographic images and quantitative parameters of perfusion, cell viability, proliferation 
and/or metabolic activity of tissues. These images result from the use of different substances of biological interest (sugars, amino 
acids, metabolic precursors, hormones) labelled with positron-emitting radionuclides (PET radiopharmaceuticals). Fusion of the 
aforementioned important functional information with the morphological detail provided by CT as PET/CT provides clinicians 
with a sensitive and accurate one-step whole-body diagnostic and prognostic tool, which directs and changes patient management. 
Hence PET/CT is currently the most widely used molecular imaging technology for a patient-tailored treatment approach. In 
these recommendations we outline which oncological and non-oncological indications are appropriate for PET/CT. Once each 
combination of pathology and clinical indication is defined, a recommendation is given as: 1. Recommended; 2. Recommended in 
select cases; 3. May be considered; or 4. Not recommended.
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it difficult to ensure its optimal use. When used appropriately, 
PET/CT frequently provides powerful clinical information that 
improves patient outcomes and may lead to significant savings in 
the overall management costs of patients (e.g. by avoiding the cost 
of futile surgery and/or chemotherapy). Its inappropriate use has the 
potential risk of unjustifiable additional costs in patient management. 
There is frequently confusion among referring clinicians (and even 
imaging specialists) about the role of PET/CT in the management 
of a multitude of oncological and non-oncological conditions. The 
College of Nuclear Physicians (CNP) is the examining body for all 
nuclear medicine specialists in training. It is therefore also the body 
primarily responsible for the examination of PET/CT training in 
this country. In order to address these challenges, the CNP made the 
decision in late 2014 to draw up this document to provide guidance 
to referring clinicians (especially oncologists), nuclear medicine 
physicians, radiologists, and health insurers. This document strives 
to include recommendations on current indications for the use of 
PET/CT that represent the state of knowledge at the time of writing, 
and taking into account tracer availability in South Africa (SA). These 
indications are (for the most part) restricted to conditions where 
there is sufficient evidence of patient benefit, improved outcomes 
and altered management strategies and will be updated periodically 
as new evidence emerges.
It should be noted that recommendations and guidelines regarding 
the use of FDG-PET and PET/CT in oncology (and other fields) are 
available from several international professional organisations, such 
as the European Association of Nuclear Medicine (EANM) (http://
www.eanm.org/publications/guidelines/index.php?navId=37), the 
Society of Nuclear Medicine and Molecular Imaging (SNMMI) (http://
www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=6414), 
the British Nuclear Medicine Society (BNMS) (http://www.bnms.
org.uk/procedures-guidelines/bnms-guidelines-overview/) and the 
International Atomic Energy Agency (IAEA) (http://www.iaea.org/
Publications/index.html), among others. Readers who seek further 
information are referred to these guidelines for more detailed 
information. This document is not intended to replace these 
documents, but aims to integrate and adapt this information to the 
SA context.
1.1 Indications and recommendations
The decision to approve an indication should ideally be made on 
an individual basis for each cancer type at the nuclear medicine 
physician’s discretion. It is inadequate to make a decision on the 
appropriateness of PET/CT based on pathology alone; rather, an 
explicit clinical question needs to be defined. Oncology-related 
indications have been categorised into screening, diagnosis, staging, 
early response assessment, restaging/response post therapy, suspected 
recurrence, surveillance, radiotherapy planning, and in some cases 
peptide receptor radiation therapy (PRRT) planning. These are 
further defined below:
• Screening – search for tumour in patients with increased risk but 
no known evidence of cancer
• Diagnosis – for better definition of pathology in patients with 
known/suspected cancer
• Staging – assessment of tumour spread in untreated patients with 
known cancer
• Early response assessment – assessment of therapy efficacy during 
treatment, allowing for the possibility of prognostication or 
changing ineffective therapy before its completion
• Restaging – this refers to two possible scenarios: (i) assessment 
of tumour function and spread after completion of therapy; and 
(ii) assessment of tumour function and spread in a patient with 
confirmed recurrence of disease
• Suspected recurrence – assessment of tumour recurrence in 
patients with evidence (e.g. clinical, biochemical, or radiological) 
for tumour relapse
• Surveillance – routine follow-up scanning of patients in apparent 
remission
• Radiotherapy planning – use of functional (PET) and anatomical 
(CT) information for definition of external-beam radiotherapy 
treatment volumes
• PRRT planning – a molecularly targeted radiation therapy involv-
ing the systemic administration of a radiolabelled peptide designed 
to target with high affinity and specificity receptors overexpressed 
on tumours.
Once each combination of pathology and clinical indication is defined, 
a recommendation is given as: 1. Recommended: 2. Recommended in 
select cases; 3. May be considered; or 4. Not recommended. Further 
information is set out below in order to provide clarity on how each 
of these recommendations was determined, as well as their meaning 
in terms of future decision making:
1.   Recommended: PET/CT is generally appropriate for this indication. 
There is a strong base of evidence supporting its use and/or it is 
currently recommended by international clinical guidelines.
2.   Recommended in select cases: PET/CT is appropriate for this 
indication in cases meeting clearly defined criteria. In this specific 
context there is a strong base of evidence supporting its use and/or 
it is currently recommended by international clinical guidelines.
3.   May be considered: PET/CT is generally not appropriate for this 
indication; however, it may be appropriate in individual cases 
with a strong motivation. Typically there may be some evidence 
or a strong rationale to support the use of PET/CT in special 
circumstances.
4.   Not recommended: PET/CT is generally not appropriate for this 
indication. Typically there is a low level of evidence and/or weak 
rationale for its use, and it is not endorsed by international clinical 
guidelines.
1.2 The SA context
The vast majority of professional international guidelines also apply to 
the SA setting, without the need for adaptation. However, cancer patients 
tend to present later (especially in the public sector) with more advanced 
disease, and may therefore require imaging with PET/CT earlier in 
their management. In light of the relatively high incidence of HIV 
and tuberculosis (TB) co-infection, some special considerations apply. 
This patient group may simultaneously present with a wide range of 
malignant and infective conditions, which may be difficult to distinguish 
with 18F-FDG PET. It is therefore imperative that referring physicians 
include pertinent information such as HIV status, CD4 count, viral load, 
diagnosis of previous or current TB, and current or past therapy with 
highly active antiretroviral therapy and/or anti-TB drugs.[2]
1.3 Cost-effectiveness
Data on the cost-effectiveness of PET/CT are limited, with even fewer 
studies obtained in the context of a middle-income country such as 
SA. However, many of the published data demonstrate a cost-effective 
role for PET/CT for particular oncology-related indica tions. [3] In 
some clinical scenarios the use of PET/CT can even lead to an overall 
reduction in the cost of patient management. This typically occurs 
through the avoidance of expensive invasive diagnostic procedures, 
the minimisation of futile surgery and the early cessation of 
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ineffective chemotherapeutic regimens. Unlike anatomical imaging, 
PET can predict the efficacy of chemotherapeutic regimens early 
in the course of therapy, enabling costly but ineffective therapy to 
be altered early, with benefits to patients and reduced costs. Cost-
effectiveness studies should ideally reflect local disease prevalence 
(both oncology and inflammatory conditions that may give rise to 
reduced specificity) and local costs. In SA, while data are currently 
limited, there is already some evidence that PET can be cost-effective 
and can even reduce the overall cost of treatment. [4] From a practical 
perspective there is a need to make decisions regarding the likely cost-
effectiveness of PET/CT locally that are based on available local and 
international data, as comprehensive SA cost-effectiveness studies 
are not expected to be available in the immediate future. During 
the development of these guidelines there has also been a focus on 
the appropriateness of clinical indications within the context of the 
relatively cost-constrained environment of a middle-income country.
2. 18F-FDG PET: Oncology
2.1 Central nervous system (CNS) tumours
2.1.1 Screening
FDG PET/CT is not recommended.
2.1.2 Diagnosis
• FDG PET/CT is not recommended for grading of brain tumours.[1]
• FDG PET/CT is recommended in select cases for distinguishing 
cerebral tumour from atypical infection in HIV-positive (HIV+) 
patients when anatomical imaging is inconclusive.[2,3] The greatest 
utility of FDG PET/CT may be in distinguishing infection from 
primary CNS lymphoma.[3]
• FDG PET/CT may be considered to provide optimal targets for 
stereotactic biopsy as it may increase the diagnostic yield from this 
procedure.[1]
2.1.3 Staging
• FDG PET/CT is not recommended for staging.
2.1.4 Early response assessment
• FDG PET/CT may be considered to assess response to chemo-
therapy.[1]
 2.1.5 Restaging/response post therapy
• FDG PET/CT is not recommended for restaging post therapy.[1]
• FDG PET/CT is not recommended for restaging of confirmed 
recurrence.
2.1.6 Suspected recurrence
• FDG PET/CT is recommended in select cases to distinguish 
between suspected tumour recurrence and radiation necrosis 
when magnetic resonance imaging (MRI) is inconclusive.[1,4]
2.1.7 Surveillance
• FDG PET/CT is not recommended for routine surveillance.[1]
2.1.8 Radiotherapy planning
• FDG PET/CT is not recommended for radiotherapy planning.[1]
2.1.9 Plexiform neurofibroma
2.1.9.1 Diagnosis
• FDG PET/CT may be considered in patients with suspected 
malignant transformation of plexiform neurofibroma in 
neurofibromatosis type 1.
2.2 Head and neck cancer
The head and neck cancers include malignancies arising from the 
lining of the upper aerodigestive tract such as the oral cavity, pharynx, 
larynx, paranasal sinuses and major salivary glands. Thyroid and 
central nervous system malignancies are excluded.
 2.2.1 Screening
• FDG PET/CT may be considered for screening for a second 
primary tumour. Second primary tumours can occur in up to 27% 
of head and neck squamous cell cancer patients, most frequently in 
the head and neck region, oesophagus and lungs.
2.2.2 Diagnosis
• FDG PET/CT is recommended in select cases for detection of 
an occult primary tumour site in patients presenting with cervical 
nodal metastases. (See 2.9, Malignancy of undefined primary 
origin and provisional carcinoma of unknown primary.)
2.2.3 Staging
• PET/CT is recommended in select cases for initial staging in 
patients with suspected advanced-stage disease, or tumours with a 
high propensity for spreading (such as naso- and hypopharyngeal 
carcinomas).[1]
2.2.4 Restaging/response post therapy
• FDG PET/CT is recommended for treatment response assess-
ment.[2]
2.2.5 Suspected recurrence
• FDG PET/CT is recommended for detection of recurrence in 
patients suspected clinically or on conventional imaging of having 
recurrent disease (locoregional or distant).[3]
2.2.6 Surveillance
• FDG PET/CT is not recommended in asymptomatic patients 
where there is no suspicion of recurrence.
2.2.7 Radiotherapy planning
• FDG PET/CT is recommended for radiation therapy planning.[4]
2.3 Thyroid cancer
2.3.1 Screening
• FDG PET/CT is not recommended for screening at-risk popu-
lations.
2.3.2 Diagnosis
• FDG PET/CT is not recommended for the diagnosis of thyroid 
cancers.
2.3.3 Staging
• The routine use of FDG PET/CT in differentiated thyroid 
carcinoma is not recommended.[1]
• FDG PET/CT is recommended in select cases for the 
assessment of the extent of disease in patients with Hurthle cell 
carcinomas.[1,2]
2.3.4 Restaging/response post therapy
• FDG PET/CT is recommended in select cases in evaluation 
of treatment response following systemic or local therapy of 
metastatic or locally invasive disease in poorly differentiated 
thyroid cancers and invasive Hurthle cell carcinomas.[2,3]
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• FDG PET/CT may be considered in medullary thyroid cancer 
to detect additional sites of disease in the context of a detectable 
calcitonin post thyroidectomy.
2.3.5 Suspected recurrence
• FDG PET/CT is recommended in select cases of differentiated 
thyroid cancer for detection of residual or recurrent disease when 
serum thyroglobulin is elevated and radioiodine scan is negative.[4]
• FDG PET/CT may be considered for suspected recurrence in 
treated medullary thyroid cancer, presenting with elevated cal-
citonin or carcinoembryonic antigen with normal or equivocal 
conventional imaging and octreotide scintigraphy. (Alternative 
PET-CT imaging with 68Ga-DOTATATE/NOC/TOC is recomm-
ended in these select cases).
2.3.6 Surveillance
• FDG PET/CT is not recommended.
2.3.7 Radiotherapy planning
• FDG PET/CT is not recommended.
2.4 Thymoma and thymic carcinoma
2.4.1 Screening
• FDG PET/CT is not recommended.
2.4.2 Diagnosis
• FDG PET/CT may be considered as part of the work-up of 
anterior mediastinal mass, to detect other lesions.[1] In addition, 
FDG PET/CT may assist in differentiating thymoma from thymic 
carcinoma.[2]
• FDG PET/CT is not recommended to distinguish thymic 
hyperplasia from thymoma.[1]
2.4.3 Staging
• FDG PET/CT is not recommended for staging of thymoma.[2,3]
• FDG PET/CT may be considered for staging of thymic carcin-
oma.[1]
2.4.4 Restaging/response post therapy
• FDG PET/CT may be considered for restaging of thymic carcinoma 
post therapy.[1] In such cases a baseline PET/CT is required.
• FDG PET/CT may be considered to assess treatment response in 
patients with unresectable Masaoka stage III or IV thymoma.[4] In 
such cases a baseline PET/CT is recommended for comparison.[2]
• FDG PET/CT is not recommended for response assessment in 
thymic carcinoma.
2.4.5 Suspected recurrence
• FDG PET/CT may be considered to detect suspected recurrence 
of thymoma or thymic carcinoma if CT findings are inconclusive.[3]
2.4.6 Surveillance
• FDG PET/CT is not recommended for routine follow-up.
2.4.7 Radiotherapy planning
• FDG PET/CT is not recommended for radiotherapy planning in 
thymoma or thymic carcinoma.
2.5 Breast cancer
2.5.1 Screening
• FDG PET/CT is not recommended.
2.5.2 Diagnosis
• FDG PET/CT is not recommended for routine use in diagnosis.
• FDG PET/CT may be considered in selected patients with dense 
breasts, where the sensitivity of mammography is poor.[1]
2.5.3 Staging
• FDG PET/CT is recommended in select cases for initial staging 
of patients with locally advanced or metastatic breast cancer or 
inflammatory breast cancer as an adjunct to conventional imaging, 
when conventional studies (such as CT or bone scan) are equi-
vocal.[1]
2.5.4 Restaging/response post therapy
• FDG PET/CT is recommended in select cases for assessment 
of response to therapy in patients whose disease is not well 
demonstrated on conventional imaging.[2]
• FDG PET/CT is recommended in select cases for differentiation 
of treatment-induced brachial plexopathy from tumour infiltration 
in symptomatic patients with an equivocal or normal MRI scan.[1]
2.5.5 Suspected recurrence
• FDG PET/CT is recommended in assessment of suspected recur-
rent disease (clinically/radiological/tumour markers/surrogate 
tumour markers).[3,4]
2.5.6 Surveillance
• FDG PET/CT is not recommended.
2.5.7 Radiotherapy planning
FDG PET/CT is not recommended.
2.6 Lymphoma
2.6.1 Hodgkin’s lymphoma (HL)
2.6.1.1 Screening
• FDG PET/CT is not recommended.
2.6.1.2 Diagnosis
• FDG PET/CT may be considered to identify amenable biopsy 
sites if these are not clinically apparent in a patient with suspected 
lymphoma.[1]
2.6.1.3 Staging
• FDG PET/CT is recommended for routine staging (including 
marrow staging) of HL.[1]
• If contrast-enhanced CT (ceCT) is used as part of staging, this should 
ideally occur in a single visit, in combination with PET/CT (i.e. 
cePET/CT), only if it has not already been performed.[1]
2.6.1.4 Early response assessment
• The use of interim PET/CT to detect early treatment response in 
HL may be considered.[1,2]
• FDG PET/CT may be considered for interim response assessment 
of patients with HD after two cycles of chemotherapy to exclude 
progression. If there is complete metabolic response (CMR) (score 
1 or 2 using Deauville criteria), there is no requirement for an end-
of-treatment response scan.
2.6.1.5 Restaging/response post therapy
• FDG PET/CT guidelines for restaging of biopsy-confirmed 
recurrence are similar to those for staging above.
• FDG PET/CT at completion of therapy is recommended in HL 
as the preferred restaging method and is prognostic of treatment 
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success and subsequent survival (assessment should be made using 
Deauville criteria).[1,3]
• FDG PET/CT is recommended at completion of salvage therapy 
in primary resistant HL and relapsed classic HL as the preferred 
restaging method.[4] The achievement of PET negativity following 
salvage is a good prognostic indicator for outcome following 
autologous stem cell transplant (ASCT) in HL. Residual FDG-
positive disease after ASCT is a poor prognostic factor.
• FDG PET/CT is recommended in select cases to determine 
treatment response in HL, when deciding whether patients with 
advanced HL who have completed BEACOPP escalated require 
radiotherapy.
2.6.2 Non-Hodgkin’s lymphoma (NHL)
2.6.2.1 Screening
• FDG PET/CT is not recommended.
2.6.2.2 Diagnosis
FDG PET/CT may be considered for identifying amenable biopsy 
sites if not clinically apparent in a patient with suspected lymphoma. [1]
2.6.2.3 Staging
• FDG PET/CT is recommended for routine staging of FDG-avid 
nodal lymphomas (diffuse large B-cell; follicular; mantle-cell; 
Burkitt’s; nodal marginal zone; lymphoblastic; anaplastic large 
T-cell; natural-killer/T-cell; angioimmunoblastic T-cell; peripheral 
T-cell).[1,3]
• FDG PET/CT is recommended for routine staging of primary 
extranodal diffuse large B-cell lymphoma (DLBCL).[3]
• FDG PET/CT is not recommended for routine staging of non-
FDG-avid nodal lymphomas (lymphoplasmacytic lymphoma/
Waldenström’s macroglobulinaemia, chronic lymphocytic 
leukaemia/small lymphocytic, marginal zone splenic, marginal 
zone unspecified).
• FDG PET/CT may be considered for staging of primary cutaneous 
NHLs except for stage IA disease and in lymphomatoid papulosis. 
FDG PET may have poor sensitivity for cutaneous lesions in these 
disorders and have a higher rate of false-negatives in detecting 
involved lymph nodes.[1]
• FDG PET/CT is not recommended for staging of mucosa-
associated lymphoid tissue (MALT) marginal zone lymphoma or 
enteropathy-type T-cell lymphoma.
• FDG PET/CT may be considered in primary CNS lymphoma to 
exclude occult systemic lymphoma.
• If contrast-enhanced CT (ceCT) is used as part of staging, this should 
ideally occur in a single visit, in combination with PET/CT (i.e. 
cePET/CT), only if it has not already been performed.[1]
2.6.2.4 Early response assessment
FDG PET/CT may be considered for assessment of response to 
initial therapy in NHL. There is as yet insufficient evidence to 
endorse the routine use of interim PET/CT in NHL to determine 
response to initial treatment.
2.6.2.5 Restaging/response post therapy
• FDG PET/CT guidelines for restaging of biopsy-confirmed 
recurrence are similar to those for staging above.
• FDG PET-CT is recommended for remission assessment in FDG-
avid nodal NHL lymphoma and primary extranodal DLBCL after 
completion of therapy (assessment should be made using Deauville 
criteria).[1]
• FDG PET/CT is recommended in select cases for restaging of 
non-FDG-avid nodal lymphomas (lymphoplasmacytic lymphoma/
Waldenström’s macroglobulinaemia, chronic lymphocytic 
leukaemia/small lymphocytic, marginal zone splenic, marginal 
zone unspecified), if there is suspicion of aggressive transform-
ation.[3]
2.6.2.6 Suspected recurrence
• FDG PET/CT is recommended in select cases to detect suspected 
relapse of FDG-avid nodal lymphoma, when no clinically apparent 
biopsy sites are available. Imaging features suggestive of relapse 
require histological confirmation. A negative PET in this context 
has a high negative predictive value.[1]
2.6.2.7 Surveillance
• FDG PET/CT is not recommended for routine follow-up of 
successfully treated NHL.[1,3]
2.6.2.8 Radiotherapy planning
• FDG PET/CT is may be considered in radiotherapy treatment 
planning in NHL, although there is currently insufficient evidence 
to support its routine use.
2.7 Langerhans cell histiocytosis (LCH)
2.7.1 Screening
• FDG PET/CT is not recommended.
2.7.2 Diagnosis
• FDG PET/CT is not recommended for diagnosis of LCH.
2.7.3 Staging
• FDG PET/CT may be considered for determining extent of 
disease at baseline.
2.7.4 Restaging/response post therapy
• FDG PET/CT may be considered to assess response to treatment. 
When used for this indication, a baseline scan is recommended.
2.7.5 Suspected recurrence
• FDG PET/CT may be considered for detecting suspected 
recurrence of disease.
2.7.6 Surveillance
• FDG PET/CT may be considered for routine surveillance. An 
optimal strategy has not been determined; radiation dosimetry is 
especially important in paediatric patients.
2.7.7 Radiotherapy planning
• FDG PET/CT is not recommended for radiotherapy planning.
2.7.8 Non-Langerhans cell histiocytoses (NLCH)
• FDG PET/CT is recommended to determine the extent of 
disease, and for monitoring treatment response and surveillance 
in Erdheim-Chester disease.
• As rare disorders, no clinical guidelines exist for other non-
Langerhans cell histiocytic disorders (e.g. Rosai-Dorfman disease, 
haemophagocytic lymphohistiocytosis, Kikuchi disease). Utility 
of FDG PET/CT has been described in many of these conditions, 
however. Because of the inflammatory nature of lesions in 
histiocytic disorders, sites of disease are expected to be FDG-avid. 
As such FDG PET/CT may be considered for the same indications 
IN PRACTICE
111       January 2016, Vol. 106, No. 1
as listed under LCH, where the results of the scan will affect 
management.
2.7.9 Other lymphoproliferative disorders
• FDG PET/CT may be considered in staging and restaging of post-
transplant lymphoproliferative disorder.
• FDG PET/CT may be considered in staging and restaging of 
other lymphoproliferative disorders, such as lymphomatoid 
granulomatosis and Castleman disease. As rare disorders, 
evidence for the utility of FDG PET/CT in these conditions is 
limited.
2.8 Multiple myeloma
2.8.1 Screening
• FDG PET/CT is not recommended.
2.8.2 Diagnosis
• FDG PET/CT may be considered under certain circumstances 
when standard workup is ambiguous or inconclusive.[1] FDG 
PET/CT may be considered to distinguish between patients 
with definite active myeloma (FDG-positive) and patients with 
monoclonal gammopathy of unknown significance or smouldering 
disease (both of which are FDG-negative).[2]
2.8.3 Staging
• FDG PET/CT is recommended in select cases for patients with 
apparently solitary plasmacytoma to exclude early bone marrow 
involvement, but cannot be used as a substitute for conventional 
imaging methods.[2]
• FDG PET/CT may be considered to exclude extensive or 
extramedullary disease if this will impact therapeutic decisions.[3]
2.8.4 Restaging/response post therapy
• FDG PET/CT is not recommended for restaging of multiple 
myeloma after definitive therapy.
• FDG PET/CT may be considered to assess treatment response in 
multiple myeloma.[4] If used in this context, a baseline PET/CT is 
recommended.
2.8.5 Suspected recurrence
• FDG PET/CT is recommended in select cases for suspected 
relapse in patients with non-secretory myeloma or predominantly 
extramedullary disease.
2.8.6 Surveillance
• FDG PET/CT may be considered for routine follow-up of multiple 
myeloma as clinically indicated.[4]
2.8.7 Radiotherapy planning
• FDG PET/CT is not recommended in radiotherapy planning of 
plasmacytoma or multiple myeloma (insufficient evidence).
2.9  Malignancy of undefined primary origin (MUO)  
and provisional carcinoma of unknown primary 
(CUP)
2.9.1 MUO
MUO is metastatic malignancy identified on the basis of 
a limited number of tests, without an obvious primary site, 
before comprehensive investigation. Investigations that form the 
recommended initial work-up of MUO are covered by several 
international guidelines.
2.9.2 Provisional CUP
Provisional CUP is metastatic epithelial or neuroendocrine 
malig nancy identified on the basis of histology/cytology, with 
no primary site detected despite a selected initial screen of 
investigations, before specialist review and possible further 
specialised investigations.
2.9.3 Confirmed CUP
Confirmed CUP is metastatic epithelial or neuroendocrine 
malignancy identified on the basis of final histology, with no primary 
site detected despite a selected initial screen of investigations, 
specialist review, and further specialised investigations as appropriate.
2.9.4 Screening 
• FDG PET/CT is not recommended.
2.9.5 Diagnosis
2.9.5.1 MUO
• FDG PET/CT is not recommended in the routine investigation of 
these patients.[1,2]
2.9.5.2 Provisional CUP
• FDG PET/CT is recommended in select cases in patients 
presenting with cervical lymphadenopathy with no primary 
tumour identified on ear, nose and throat panendoscopy if radical 
treatment is considered to be an option.[3]
2.9.6 Staging
2.9.6.1 Provisional CUP
• FDG PET/CT is recommended in select cases to detect disease 
amenable to local or regional therapy[3] or when curative 
therapy is planned,[4] such as in the case of extracervical 
presentation of a single metastatic lesion and a negative 
conventional work-up.
2.9.7 Restaging/response post therapy
• FDG PET/CT is not recommended to assess response to initial 
treatment.
2.9.8 Suspected recurrence
• FDG PET/CT is not recommended to restage after completing 
therapy.
2.9.9 Surveillance
• FDG PET/CT is not recommended for surveillance.
2.9.10 Radiotherapy planning
• FDG PET/CT is not recommended for radiotherapy planning.
2.10 Paraneoplastic neurological syndrome (PNS)
2.10.1 Screening
The optimal strategy for tumour screening in the context of a PNS is 
directed based on the most likely primary. Most likely primary site is 
assessed on (among other factors) the clinical syndrome and type of 
paraneoplastic antibody detected:[1]
2.10.1.1 Likely small-cell lung cancer
• FDG PET/CT is recommended if an initial CT thorax is negative.
2.10.1.2 Likely thymoma
• FDG PET/CT is recommended if an initial CT thorax is negative.
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2.10.1.3 Likely breast carcinoma
• FDG PET/CT is recommended if mammography and MRI breast 
are negative.
2.10.1.4 Likely teratoma
• FDG PET/CT is not recommended.
2.10.1.5 Likely ovarian carcinoma
• FDG PET/CT may be considered if transvaginal ultrasound ± 
CT-pelvis/abdomen are negative.
2.10.1.6 Likely testicular tumour
• FDG PET/CT is not recommended.
• If no paraneoplastic antibodies are detected, the patient has a 
classic PNS, and the neurological condition is deteriorating, total-
body FDG PET/CT, is recommended if initial recommended 
investigations directed towards a likely primary site are negative.[1]
• Because of the high negative predictive value of initial PET/CT, 
the repeated use of FDG PET/CT may be considered as part of 
screening in patients with PNS and paraneoplastic antibodies 
in whom no primary tumour has been identified at baseline, if 
suspicion of a malignancy remains high.[2]
2.11 Melanoma
2.11.1 Screening
• FDG PET/CT is not recommended.
2.11.2 Diagnosis
• FDG PET/CT is not recommended.
2.11.3 Staging
• FDG PET/CT is not recommended in early-stage patients (AJCC 
stages I and II).
• FDG PET/CT is recommended in select cases for detection and 
localisation of potential extranodal metastatic lesions in initial 
evaluation of patients with clinically suspected advanced-stage 
disease (AJCC stage III and IV),[1] and for staging of patients with 
known disseminated melanoma to assess extent of disease prior to 
treatment.[1]
• FDG PET/CT is recommended in select cases where metastasec-
tomy is planned, to exclude disease that might make surgery 
inappropriate.[2]
2.11.4 Restaging/response post therapy
• FDG PET/CT is recommended in select cases for evaluation 
of the extent of metastatic disease burden in recurrent disease 
following treatment.[3]
• FDG PET/CT is recommended in select cases to assess response 
to isolated limb infusion.[4]
2.11.5 Surveillance
• FDG PET/CT is not recommended for routine follow-up.[3]
2.11.6 Suspected recurrence
• FDG PET is recommended in select cases of suspected recurr ence 
where symptom-guided conventional imaging is equivocal.[3]
2.12 Lung cancers
2.12.1 Non-small-cell lung cancer (NSCLC)
Definition: Solitary pulmonary nodule (SPN): a single, well-circum-
scribed, radiographic opacity ≤3 cm in diameter that is completely 
surrounded by aerated lung (i.e. not touching mediastinum or 
hilum), not associated with atelectasis, hilar enlargement, or pleural 
effusion.
2.12.1.1 Screening
• FDG PET/CT is not recommended for screening at-risk 
populations.
2.12.1.2 Diagnosis
• FDG PET/CT is recommended in select cases in the 
investigation of a solid, non-calcified SPN ≥8 mm in diameter 
that is suspicious for malignancy.[1] FDG PET/CT has a good 
negative predictive value in this context, which allows for 
radiological follow-up of low-risk patients. The positive 
predictive value of FDG PET/CT in identifying malignant 
nodules is generally good but is reduced in regions with a 
high prevalence of infectious lung disease (e.g. TB);[2] it is not 
possible to reliably distinguish between infective and malignant 
nodules on the basis of PET.[1]
2.12.1.3 Staging
• FDG PET/CT is recommended in select cases as part of staging 
for patients with potentially curable disease (on CT staging) and 
who are fit for definitive therapy.[1]
2.12.1.4 Restaging/response post therapy
• FDG PET/CT may be considered after induction therapy to 
exclude progression of disease.[1]
• For patients with biopsy-confirmed recurrence PET/CT may be 
considered for restaging to assist selection of therapy.
2.12.1.5 Suspected recurrence
• FDG PET/CT may be considered when findings on follow-up 
CT are equivocal for neoplasm. When used in this context, biopsy 
confirmation is necessary for positive PET findings.[1]
2.12.1.6 Surveillance
• FDG PET/CT is not recommended for routine follow-up of 
NSCLC.[1]
2.12.1.7 Radiotherapy planning
• FDG PET/CT may be considered to assist radiotherapy planning, 
especially when there is significant atelectasis or when intravenous 
(IV) contrast is contraindicated.[1]
2.12.2 Small-cell lung cancer (SCLC)
2.12.2.1 Screening
• FDG PET/CT is not recommended for screening populations at 
risk.
2.12.2.2 Diagnosis
• FDG PET/CT is recommended in select cases for the investi-
gation of a solid, non-calcified SPN ≥8 mm in diameter that is 
suspicious for malignancy.[1] FDG PET/CT has a good negative 
predictive value in this context, which allows for radiological 
follow-up of low-risk patients. The positive predictive value 
of FDG PET/CT in identifying malignant nodules is generally 
good but is reduced in regions with a high prevalence of 
infectious lung disease (e.g. TB);[2] it is not possible to reliably 
distinguish between infective and malignant nodules on the 
basis of PET.[1]
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2.12.2.3 Staging
• FDG PET/CT is recommended in select cases as part of 
staging for patients with suspected limited-stage disease, 
who are potential candidates for radical management and in 
whom the detection of occult disease would alter manage-
ment.[3]
2.12.2.4 Restaging/response post therapy
• FDG PET/CT is not recommended for response assessment in 
SCLC.
• PET/CT is not recommended for restaging of confirmed 
recurrence.
2.12.2.5 Suspected recurrence
• FDG PET/CT is not recommended after definitive therapy.
2.12.2.6 Surveillance
• FDG PET/CT is not recommended for routine follow-up of 
SCLC.[3]
2.12.2.7 Radiotherapy planning
• FDG PET/CT may be considered to assist radiotherapy planning. [3]
2.13 Primary pleural malignancy/mesothelioma
2.13.1 Screening
• FDG PET/CT is not recommended.
2.13.2 Diagnosis
• FDG PET/CT is not recommended for routine diagnosis of 
mesothelioma.
• FDG PET/CT may be considered in patients with suspected 
primary pleural malignancy, in whom conventional imaging and 
pleural biopsy are inconclusive, in order to guide choice of biopsy 
site. In these cases PET/CT should be performed prior to talc 
pleurodesis.
2.13.3 Staging
• FDG PET/CT is recommended in select cases for staging of 
patients being considered for surgery as part of a curative strategy, 
who have clinical stage I - III disease with epithelial or mixed 
histology.[4] In these patients, PET/CT should be performed before 
any pleurodesis.
2.13.4 Restaging/response post therapy
• FDG PET/CT is not recommended to assess treatment 
response.
• FDG PET/CT is not recommended to restage patients after 
definitive therapy.
• FDG PET/CT is not recommended for restaging of biopsy-
confirmed recurrence.
2.13.5 Suspected recurrence
• FDG PET/CT may be considered to detect suspected recurrence 
in mesothelioma.
2.13.6 Surveillance
• FDG PET/CT is not recommended for routine follow-up after 
definitive therapy.
2.13.7 Radiotherapy planning
• FDG PET/CT may be considered in radiotherapy planning.
2.14 Gastrointestinal tract (GIT)
2.14.1 Oesophageal cancer
2.14.1.1 Screening
• FDG PET/CT is not recommended.
2.14.1.2 Diagnosis
• FDG PET/CT is not recommended for the diagnosis of 
oesophageal cancer.[1]
2.14.1.3 Staging
• FDG PET/CT is recommended in select cases for staging in 
patients being considered for radical therapy.[2]
2.14.1.4 Restaging/response post-therapy
• FDG PET/CT is recommended in select cases for restaging after 
neoadjuvant treatment in patients being considered for radical therapy.[2]
2.14.1.5 Suspected recurrence
• FDG PET/CT is recommended in select cases to detect recurrence 
when other imaging is negative or equivocal.[2]
2.14.1.6 Surveillance
• FDG PET/CT may be considered for routine follow-up of patients 
given the high incidence of recurrence.
2.14.1.7 Radiotherapy planning
• FDG PET/CT may be considered for radiotherapy planning as 
several studies have shown a good correlation between FDG-PET 
and pathology-based tumour length.
2.14.2 Gastric cancer
2.14.2.1 Screening
• FDG PET/CT is not recommended.
2.14.2.2 Diagnosis
• FDG PET/CT is not recommended for the diagnosis of gastric 
cancer. Diagnosis is established by endoscopy and biopsy.
2.14.2.3 Staging
• FDG PET/CT may be considered for staging owing to an increased 
detection of nodal and distant metastatic disease.[1]
2.14.2.4 Restaging/response post therapy
• FDG PET/CT may be considered for restaging after definitive therapy.[1]
• FDG PET/CT may be considered for assessing the response to 
preoperative chemotherapy.
2.14.2.5 Suspected recurrence
• FDG PET/CT is not recommended in cases of suspected recur-
rence.[1]
2.14.2.6 Surveillance
• FDG PET/CT may be considered in the post-treatment surveil-
lance of patients.[1]
2.14.2.7 Radiotherapy planning
• FDG PET/CT is not recommended.[1]
2.14.3 Pancreatic adenocarcinoma
2.14.3.1 Screening
• FDG PET/CT is not recommended.
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2.14.3.2 Diagnosis
• FDG PET/CT is not recommended as it offers no benefit over 
the current primary diagnostic tools in diagnosing pancreatic 
cancer.
2.14.3.3 Staging
• FDG PET/CT recommeded in select cases for staging of patients 
with potentially operable pancreatic adenocarcinoma where 
conventional imaging is equivocal, and a positive PET/CT would 
lead to a decision not to operate.[2]
2.14.3.4 Early response assessment
• FDG PET/CT is not recommended.[1]
2.14.3.5 Restaging/response post therapy
• FDG PET/CT is not recommended.[1]
2.14.3.6 Suspected recurrence
• FDG PET/CT may be considered in cases of suspected recurrence, 
where other imaging is equivocal or negative.[2]
2.14.3.7 Surveillance
• FDG PET/CT may be considered in the post-treatment surveil-
lance of patients.[1]
2.14.3.8 Radiotherapy planning
• FDG PET/CT may be considered for target volume delineation 
and dose intensification.[1]
2.14.4 Colorectal cancer
2.14.4.1 Screening
• FDG PET/CT is not recommended.
2.14.4.2 Diagnosis
• FDG PET/CT is not recommended for the diagnosis of colorectal 
cancer.[1]
2.14.4.3 Staging
• FDG PET/CT is recommended in select cases for patients in 
whom potentially resectable metastases have been detected on 
conventional imaging.[3]
• FDG PET/CT may be considered in patients in whom conventional 
imaging is equivocal.[2]
2.14.4.4 Early response assessment
• FDG PET/CT may be considered during chemotherapy in 
advanced colorectal cancer to identify ineffective treatment in 
non-responders.[4]
2.14.4.5 Restaging/response post therapy
• FDG PET/CT is recommended in select cases for restaging of 
patients with confirmed recurrence being considered for radical 
treatment and/or metastatectomy.[1,2]
• FDG PET/CT may be considered after local ablative therapy 
of liver metastases to identify residual tumour at an early 
stage.[2]
• FDG PET/CT may be considered after preoperative radiotherapy 
for rectal cancer as 18F-FDG PET/CT has been shown to correlate 
better with pathology than conventional imaging.[4]
• FDG PET/CT may be considered for the evaluation of indetermi-
nate presacral masses post treatment.
2.14.4.6 Suspected recurrence
• FDG PET/CT is recommended to detect recurrence in cases of 
rising tumour markers.
• FDG PET/CT may be considered in cases of clinically suspected 
recurrence with equivocal findings on other imaging.[2]
2.14.4.7 Surveillance
• FDG PET/CT may be considered for routine follow-up of patients, 
as in limited studies it has been shown to detect recurrence at an 
earlier stage.
2.14.4.8 Radiotherapy planning
• FDG PET/CT is not recommended for radiotherapy planning.[1]
2.14.5 Anal cancer
2.14.5.1 Screening
• FDG PET/CT is not recommended.
2.14.5.2 Diagnosis
• FDG PET/CT is not recommended.
2.14.5.3 Staging
• FDG PET/CT is not recommended for routine use as it has not 
been validated and it should not replace diagnostic CT.
• FDG PET/CT may be considered for node-positive disease and 
T2-4 N0 disease to confirm staging before surgery.
2.14.5.4 Restaging/response post therapy
• FDG PET/CT may be considered for restaging of patients 
with persistent, progressive or recurrent disease who are being 
considered for salvage surgery.
2.14.5.5 Suspected recurrence
• FDG PET/CT is not recommended.
2.14.5.6 Surveillance
• FDG PET/CT is not recommended.
2.14.5.7 Radiotherapy planning
• FDG PET/CT may be considered.
2.15  Hepatobiliary cancers (hepatocellular 
carcinoma (HCC), gallbladder carcinoma and 
cholangiocarcinoma)
2.15.1 Screening
• FDG PET/CT is not recommended.
2.15.2 Diagnosis
• FDG PET/CT is not recommended.
2.15.3 Staging
• FDG PET/CT is not recommended for routine staging of 
HCC.
• FDG PET/CT may be considered to detect distant and nodal 
metastases in patients with biliary cancer and otherwise potentially 
resectable disease.[1] There is, however, a high risk of false-negative 
studies in mucinous adenocarcinomas.
2.15.4 Restaging/response post therapy
• FDG PET/CT is not recommended for restaging of confirmed 
recurrence of HCC or biliary cancer.
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• FDG PET/CT is not recommended to assess treatment response 
in HCC or biliary cancers (insufficient evidence).
2.15.5 Suspected recurrence
• FDG PET/CT is not recommended.
2.15.6 Surveillance
• FDG PET/CT is not recommended in routine follow-up of 
patients with treated HCC or biliary cancers.
2.15.7 Radiotherapy planning
• FDG PET/CT is not recommended in radiotherapy planning for 
HCC or biliary cancers.
2.16 Sarcoma (GIST is treated separately, see 2.17)
2.16.1 Screening
• FDG PET/CT is not recommended.
2.16.2 Diagnosis
• FDG PET/CT is not recommended in the routine diagnosis of 
sarcoma.
• FDG PET/CT may be considered to detect malignant transforma-
tion in patients with neurofibromatosis 1 (see section on plexiform 
neurofibroma).
2.16.3 Staging
• FDG PET/CT is recommended in select cases in patients with 
soft-tissue sarcoma and suspected isolated metastases who are 
potential candidates for curative surgery.[2]
• FDG PET/CT may be considered for staging of soft-tissue sarcoma, 
but does not replace established radiological investigations.[2] FDG 
PET/CT may be useful in prognostication and grading (since biopsy 
may not be representative)[2] and is especially beneficial in high-
grade extremity lesions that are larger than 3 cm, firm and deep.
• FDG PET/CT may be considered in staging of Ewing’s sarcoma 
and osteosarcoma.
• FDG PET/CT may be considered in staging of chordoma.
2.16.4 Restaging/response post therapy
• FDG PET/CT may be considered for restaging of recurrent 
rhabdomyosarcoma but does not replace established radiological 
investigations.[2]
• FDG PET/CT may be considered for restaging after definitive 
therapy of soft-tissue and skeletal sarcomas (provided a baseline 
scan was obtained).
• FDG PET/CT may be considered for assessing response to 
treatment in both skeletal and soft-tissue sarcomas. In such cases 
comparison with a baseline scan is required.
• FDG PET/CT may be considered after neoadjuvant therapy of 
high-grade osteosarcoma to assess resectability (in comparison 
with a baseline PET/CT study).
2.16.5 Suspected recurrence
• FDG PET/CT may be considered for detection of suspected 
recurrence of sarcoma in order to guide biopsy.[2]
• FDG PET/CT may be considered prior to radical amputation for 
recurrent soft-tissue sarcoma to exclude other sites of disease.
2.16.6 Surveillance
• FDG PET/CT is not recommended for routine follow-up of 
previously treated patients with soft-tissue sarcomas.
• FDG PET/CT may be considered for post-therapy surveillance of 
treated Ewing’s sarcoma and osteosarcoma.
2.16.7 Radiotherapy planning
• FDG PET/CT may be considered in radiotherapy planning of 
high-grade sarcomas. This is based on minimal evidence but a 
strong rationale.[2]
2.17 Gastrointestinal stromal tumour (GIST)
2.17.1 Screening
• FDG PET/CT is not recommended.
2.17.2 Diagnosis
• FDG PET/CT is not recommended.
2.17.3 Staging
• FDG PET/CT is recommended in select cases for GIST prior to 
the initiation of imatinib (Gleevec) therapy in patients with tumours 
that are marginally resectable or with risk of significant morbidity,[3] 
but may yet undergo curative surgery. In these cases, PET/CT may 
assist in making a timely decision for or against surgery.[3] PET/CT 
does not replace CT or MRI in staging these patients.
• FDG PET/CT may be considered in patients with definitively 
unresectable disease who will be started on imatinib, as a baseline 
measure against which future PET/CT for treatment response 
might be performed.[3]
• FDG PET/CT may be considered for staging of GIST patients with 
allergy to CT contrast and inconclusive MRI.
2.17.4 Restaging/response post therapy
• FDG PET/CT is recommended in select cases for patients who 
may be future candidates for curative resection, to assess initial 
treatment response after 2 - 4 weeks of imatinib therapy, if the 
tumour shows uptake on baseline PET/CT.[4]
• FDG PET/CT is not recommended for routine restaging of 
patients who undergo definitive therapy (surgery).[4]
2.17.5 Suspected recurrence
• FDG PET/CT may be considered for detecting suspected 
recurrence of previously definitively treated GIST, when CT or 
MRI is ambiguous.
2.17.6 Surveillance
• FDG PET/CT is not recommended for routine follow-up in 
definitively treated disease or in patients on imatinib mainten ance. [4]
2.17.7 Radiotherapy planning
• FDG PET/CT is not recommended in radiotherapy planning for 
GIST.
2.18 Genitourinary system
2.18.1 Renal cell carcinoma (RCC)
• FDG PET/CT may be considered for extrarenal metastases in 
staging and restaging.
• Currently there is insufficient evidence to support the use of 
FDG PET/CT in diagnosis, or surveillance post nephrectomy in 
RCC. FDG PET/CT in RCC for these indications is therefore not 
recommended.[1]
• FDG PET/CT may be considered for the assessment of tumour 
response to molecular-triggered therapies when there is minimal 
change in volume (on radiological assessment).[2]
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2.18.2 Ureteric and urethral carcinoma
• Currently there is insufficient evidence to support the use of FDG 
PET/CT in ureteric and urethral cancers. Existing clinical guidelines 
do not include a role for FDG PET/CT in this condition.[3] FDG 
PET/CT in these malignancies is therefore not recommended.
2.18.3 Bladder cancer
No main clinical guidelines currently endorse a role for FDG PET/
CT in bladder cancer.[4]
2.18.3.1 Screening
• FDG PET/CT is not recommended.
2.18.3.2 Diagnosis
• FDG PET/CT is not recommended.
2.18.3.3 Staging
• FDG PET/CT may be considered in the staging work-up of 
patients with muscle-invasive bladder cancer who are eligible for 
radical cystectomy when conventional CT and bone scintigraphy 
are negative or inconclusive for metastases.
2.18.3.4 Restaging/response post therapy
• FDG PET/CT is not recommended for response post therapy.
• FDG PET/CT may be considered for distant metastases in restaging.
2.18.3.5 Suspected recurrence
• FDG PET/CT is not recommended.
2.18.3.6 Surveillance
• FDG PET/CT is not recommended.
2.18.3.7 Radiotherapy planning
• FDG PET/CT is not recommended.
2.19 Male reproductive system
2.19.1 Testicular cancer
2.19.1.1 Screening
• FDG PET/CT is not recommended.
2.19.1.2 Diagnosis 
• FDG PET/CT is not recommended.
2.19.1.3 Staging
• FDG PET/CT is not recommended for initial staging.
2.19.1.4 Restaging/response post therapy
• FDG PET/CT is recommended in select cases, in pure seminoma 
with residual tumour >3 cm and normal marker levels post 
chemotherapy: to detect viable residual tumour. In such cases, PET 
should be performed ≥6 weeks after last chemotherapy to reduce 
the incidence of false-positive results.[1]
• FDG PET/CT may be considered in pure seminoma with residual 
tumour <3 cm and normal marker levels post chemotherapy: 
to detect viable residual tumour. In this context, the positive 
predictive value of PET is lower and surveillance is preferred. If 
performed in such cases, PET should be performed ≥6 weeks after 
last chemotherapy to reduce incidence of false-positive results.
2.19.1.5 Suspected recurrence
• FDG PET/CT may be considered for detection of suspected recurrence 
of testicular cancer when other imaging techniques are not helpful.[2]
2.19.1.6 Surveillance
• FDG PET/CT is not recommended for routine surveillance of 
testicular cancer after definitive therapy.
2.19.1.7 Radiotherapy planning
• FDG PET/CT is not recommended for radiotherapy planning.
2.19.2 Penile carcinoma
2.19.2.1 Screening
• FDG PET/CT is not recommended.
2.19.2.2 Diagnosis
• FDG PET/CT is not recommended.
2.19.2.3 Staging (ab initio and biopsy-confirmed recurrence)
• FDG PET/CT may be considered in patients with palpable 
inguinal nodes and who have potentially resectable disease on CT 
or MRI; FDG detects pelvic lymph node- and distant metastases.[3]
2.19.2.4 Restaging/response post therapy
• FDG PET/CT is not recommended.
2.19.2.5 Suspected recurrence
• FDG PET/CT is not recommended.
2.19.2.6 Routine follow-up (surveillance)
• FDG PET/CT is not recommended for surveillance post definitive 
therapy.
2.19.2.7 Radiotherapy planning
• FDG PET/CT may be considered to assist planning of neo adjuvant 
radiotherapy (strong rationale).
2.19.3 Prostate cancer
• FDG PET/CT is not recommended in prostate cancer (please refer 
to section on non-18F-FDG PET).
2.20 Female reproductive system
2.20.1 Cervical cancer
2.20.1.1 Screening
• FDG PET/CT is not recommended.
2.20.1.2 Diagnosis
• FDG PET/CT is not recommended.
2.20.1.3 Staging
• FDG PET/CT is recommended in select cases for initial staging, 
in locally advanced cervical cancer being considered for radical 
chemoradiotherapy.[1]
2.20.1.4 Restaging/response post therapy
• FDG PET/CT is recommended in select cases for restaging 
in locally advanced disease being considered for radical 
chemoradiotherapy.[2]
2.20.1.5 Suspected recurrence
• FDG PET/CT is recommended in select cases for detection of 
recurrent disease when other imaging is equivocal.[3]
2.20.1.6 Surveillance
• FDG PET/CT is not recommended for routine follow-up.
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2.20.1.7 Radiotherapy planning
• FDG PET/CT may be considered for radiotherapy planning.[1]
2.20.2 Other gynaecological malignancies
2.20.2.1 Screening
• FDG PET/CT is not recommended for screening at-risk popu-
lations.
2.20.2.2 Diagnosis
• FDG PET/CT is not recommended for diagnosis of ovarian 
cancer.
• FDG PET/CT is not recommended for diagnosis of endometrial 
cancer.
2.20.2.3 Staging
• FDG PET/CT may be considered for staging of patients with 
endometrial cancer considered for surgery.
• FDG PET/CT may be considered for staging of patients with 
vulval carcinoma considered for surgery.[1]
• FDG PET/CT may be considered for staging of ovarian can-
cer, complementary to diagnostic CT in selected patients 
preoperatively.
2.20.2.4 Restaging/response post therapy
• FDG PET/CT may be considered for restaging of patients with 
endometrial cancer considered for surgery.
• FDG PET/CT may be considered for restaging of patients with 
vulval carcinoma considered for surgery.[1]
• FDG PET/CT is not recommended for assessing response to therapy.
2.20.2.5 Suspected recurrence
• FDG PET/CT is recommended in select patients for detection of 
tumour recurrence in ovarian carcinoma with rising CA125 levels 
and equivocal or negative conventional imaging.[4]
• FDG PET/CT is recommended in select patients for suspected 
recurrence of endometrial cancer when other imaging modalities 
are equivocal.
• FDG PET/CT may be considered for suspected recurrence of 
vulval carcinoma when other imaging modalities are equivocal.[1]
2.20.2.6 Surveillance
• FDG PET/CT is not recommended for routine follow-up.
2.20.2.7 Radiotherapy planning
• FDG PET/CT is not recommended for radiotherapy planning.
3. Non-18F-FDG PET
3.1  Neuroendocrine tumours: Somatostatin receptor 
PET/CT (68Ga-SSTR PET/CT)
Neuroendocrine tumours (NETs) comprise a heterogeneous group 
of neoplasms that arise from endocrine cells within glands (adrenal 
medulla, pituitary, parathyroid) or from endocrine islets in the 
thyroid, the pancreas, or the respiratory and gastrointestinal tract. 
When histology is available it is important to distinguish between 
well/intermediately differentiated NETs (Ki67 <20%) and poorly 
differentiated NETs (Ki67 >20%). FDG PET remains the preferred 
modality for staging a poorly differentiated NET. Well/intermediately 
differentiated NETs are likely to be better visualised with somatostatin 
receptor PET/CT using 68Ga-DOTA-conjugated peptide PET/CT 
(68Ga-SSTR PET/CT). [1] Routinely used PET tracers include Ga-68-
DOTA-TATE/TOC/NOC.
The likelihood of tumour detection with 68Ga-SSTR PET/CT can also 
be predicted to some extent based on tumour type:
• Tumours with high expression of receptors: gastroenteropancreatic 
tumours (e.g. carcinoids, gastrinoma, glucagonoma, VIPoma, 
etc.), functioning and non-functioning; sympathoadrenal system 
tumours; pituitary adenoma; medulloblastoma; Merkel cell 
carcinoma; small-cell lung cancer (mainly primary tumours) and 
meningioma.
• Tumours with variable expression of receptors: insulinoma, phaeo-
chromocytoma, paraganglioma, neuroblastoma, ganglioneuroma 
and medullary thyroid carcinoma.
• Tumours with low expression of receptors: breast carcinoma, 
melanoma, lymphoma, prostate carcinoma, non-small-cell lung 
cancer, sarcomas, renal cell carcinoma, differentiated thyroid 
carcinoma, astrocytoma and ependymoma.
68Ga-SSTR PET/CT and FDG PET/CT frequently have a 
complementary role given the heterogeneity in receptor expression at 
different tumour sites and the variable positivity of each for a given 
tumour grade and type.
3.1.1 Screening
• 68Ga-SSTR PET is not recommended for screening at-risk 
populations.
3.1.2 Diagnosis
• 68Ga-SSTR PET may be considered for the detection of primary 
NETs (CUP-NETs).[2] Carcinoma of unknown primary (CUP) is 
defined as a biopsy-proven secondary lesion without any evidence of 
primary site after physical examination and conventional imaging 
tests (MRI, CT and ultrasound).
• 68Ga-SSTR PET may be considered in the diagnostic work-up 
of patients with suspected NETs due to clinical symptoms, 
elevated levels of tumour markers or in indeterminate 
tumours suggestive of NET, especially in suspected thoracic 
or gastro-entero-pancreatic neuroendocrine tumours (GEP-
NETs).
3.1.3 Staging
• 68Ga-SSTR PET is recommended in select cases for preoperative 
staging to localise primary tumours and detect sites of metastatic 
disease.[3]
• 68Ga-SSTR PET may be considered for baseline staging of patients 
with GEP-NETs that will be managed medically or with an 
expectant strategy.
• 68Ga-SSTR PET may be considered for staging of phaeo chromo-
cytoma, paraganglioma, bronchial carcinoid, neuro blastoma, 
medullary thyroid cancer, multiple endocrine neoplasia type 2, 
and Merkel cell cancer.
3.1.4 Early response assessment
• 68Ga-SSTR PET may be considered after the first PRRT cycle 
used for treatment of NET, as a prognostic measure, although 
there is currently insufficient evidence for its routine use in this 
indication.
3.1.5 Restaging/response post therapy
• 68Ga-SSTR PET may be considered for restaging and for treatment 
response evaluation, although there is insufficient evidence to 
recommend this routinely. In such cases, comparison with a 
baseline scan is recommended.[1]
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3.1.6 Suspected recurrence
• 68Ga-SSTR PET may be considered to follow up patients with 
known disease in order to detect recurrent disease when suspected 
clinically or due to rising tumour markers.
3.1.7 Surveillance
• 68Ga-SSTR PET is recommended as part of routine follow-up 
of all GEP-NET tumours after 18 - 24 months if expression of 
somatostatin receptor 2a has been proven on tumour cells[2] or 
baseline 68Ga-SSTR PET was positive (strong rationale).
3.1.8  Peptide receptor radiation therapy (PRRT)/radiotherapy 
planning
• 68Ga-SSTR PET may be considered to determine SST receptor 
status visually as well as by using semiquantitative parameters such 
as standardised uptake value (patients with SST receptor-positive 
tumours are more likely to respond to octreotide therapy). This is 
based on limited evidence, and strong rationale.
• 68Ga-SSTR PET is recommended to select patients with metastatic 
disease who are being considered for PRRT (with 177Lu or 
90Y-DOTA-peptides).[1]
• 68Ga-SSTR PET is not recommended for external beam radio-
therapy planning In NET tumours.
3.2 Neuroendocrine tumours: 18F-FDG PET/CT
• FDG PET/CT is recommended in proven malignant pheo-
chromocytoma, for staging.[4]
• FDG PET/CT may be considered for follow-up post therapy 
in select cases of phaeochromocytoma (proven malignant; 
SDHB mutation; extra-adrenal primary; phaeochromocytoma/
paraganglioma without relevant preoperative hormone secretion). 
In such cases, imaging should be repeated at least every 6 months 
during the first year and yearly afterward (lifelong), irrespective of 
negative biochemistry.
• FDG PET/CT may be considered in Merkel cell carcinoma, for 
staging.
• FDG PET/CT is recommended in staging of undifferentiated and 
non-secretory NETs of the thorax.
• FDG PET/CT may be considered as part of baseline workup of 
GEP-NETs[3] as a prognostic measure and for staging of poorly 
differentiated NETs.
• 68Ga-SSTR PET and 18F-FDG PET are likely to be complementary 
in NET imaging.
Neuroblastoma is addressed separately.
3.3 Musculoskeletal conditions: 18F-sodium fluoride
3.3.1 Diagnosis
• 18F-sodium fluoride (NaF PET/CT) may be considered in patients 
with back pain and otherwise unexplained bone pain; child abuse; 
abnormal radiographic or laboratory findings; osteomyelitis; trauma; 
inflammatory and degenerative arthritis; avascular necrosis; 
osteonecrosis of the mandible; condylar hyperplasia; metabolic 
bone disease; Paget’s disease; bone graft viability; complications 
of prosthetic joints; reflex sympathetic dystrophy; distribution 
of osteoblastic activity before administration of therapeutic 
radiopharmaceuticals for bone pain.[1]
3.4 Prostate cancer (PCA)
PET tracers for PCA: 18F-FDG, 18F-fluoroethylcholine (18F-choline), 18F-
NaF, 68Gallium-labelled prostate-specific membrane antigen (68Ga-PSMA).
3.4.1 Screening
• 18F-FDG/18F-choline/18F-NaF/68Ga-PSMA PET/CT is not recom-
mended for screening.
3.4.2 Diagnosis
• 18F-FDG PET/CT is not recommended for diagnosis. There 
is currently no evidence for using FDG in diagnosing prosate 
cancer.
• 18F-choline PET/CT may be considered for guiding re-biopsy in 
highly selected patients suffering from clinically suspected PCA 
with repeated negative prostate biopsies.
• 18F-NaF is not recommended.
• 68Ga-PSMA may be considered.
3.4.3 Staging
• 18F-FDG is not recommended for primary staging of PCA.
• 18F-choline may be considered for staging high-risk PCA patients 
(prostate-specific antigen (PSA) >20 ng/ml and Gleason score 7) if 
findings on conventional imaging are equivocal and confirmation 
or exclusion of distant disease would directly influence patient 
management.[1]
• 18F-NaF may be considered in high-risk PCA to detect bone 
metastases.[2]
• 68Ga-PSMA may be considered.
3.4.4 Restaging/response post therapy
• 18F-FDG PET/CT is not recommended for restaging after definitive 
therapy.
• 18F-choline may be considered for restaging.
• 18F-NaF is not recommended for restaging.
• 68Ga-PSMA may be considered for restaging.
• 18F-FDG PET/CT is not recommended for response post therapy.[3]
• 18F-choline is not recommended for response post therapy.
• 18F-NaF is not recommended for response post therapy.
• 68Ga-PSMA may be considered.
3.4.5 Suspected recurrence
• 18F-FDG PET/CT is not recommended for suspected 
recurrence.[4]
• 18F-choline is recommended in select cases with suspected 
recurrence in patients with a rapidly rising PSA and indeterminate 
or equivocal conventional imaging, where the results would 
directly influence patient management.[4]
• 18F-NaF is not recommended in suspected recurrence.
• 68Ga-PSMA is recommended in select cases with suspected 
recurrence.[3]
3.4.6 Surveillance
• 18F-FDG/18F-choline/18F-NaF or 68Ga-PSMA PET/CT is not 
recommended for routine follow-up.
3.4.7 Radiotherapy planning
• 18F-FDG PET/CT is not recommended.
• 18F-choline may be considered.
• 18F-NaF is not recommended.
• 68Ga-PSMA may be considered.[3]
3.4.8 Potential therapy with 177Lu-PSMA
• 68Ga-PSMA PET is recommended for select patients being 
considered for PRRT with metastatic disease or recurrence that is 
hormone refractory or not suitable for chemotherapy.[3]
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4. Paediatric oncology
4.1 Neuroblastoma
4.1.1 Screening
• FDG PET/CT is not recommended for screening at-risk popu-
lations.
4.1.2 Diagnosis
• FDG PET/CT is not recommended for the diagnosis of neuro-
blastoma.
4.1.3 Staging
• FDG PET/CT is recommended in select cases for staging if the 
tumour is not meta-iodobenzylguanidine (MIBG) avid or has a 
low affinity for MIBG. FDG PET/CT should be considered when 
the MIBG scan shows less disease than is seen on anatomical 
imaging or the clinical presentation suggests more extensive 
disease involvement.[1]
4.1.4 Restaging/response post therapy
• FDG PET/CT is recommended in select cases for restaging if 
the tumour is not MIBG avid or it has a low affinity for MIBG. 
FDG PET/CT should be considered when the MIBG scan shows 
less disease than is seen on anatomical imaging or the clinical 
presentation would suggest more extensive disease involvement.[1]
• FDG PET/CT is recommended in select cases for evaluating 
response to therapy in patients with MIBG-negative or poorly avid 
tumours.[2]
4.1.5 Suspected recurrence
• FDG PET/CT may be considered for suspected recurrence.
4.1.6 Surveillance
• FDG PET/CT is not recommended for routine follow-up.
4.1.7 Radiotherapy planning
• FDG PET/CT may be considered for radiotherapy planning.[3]
4.2 Wilms tumour
4.2.1 Screening
• FDG PET/CT is not recommended.
4.2.3 Diagnosis
• FDG PET/CT may be considered to identify a biopsy site.
4.2.4 Staging
• FDG PET/CT may be considered.
4.2.5 Early treatment response
• FDG PET/CT may be considered.
4.2.6 Restaging/response post therapy
• FDG PET/CT may be considered for restaging after completion of 
first-line treatment.
• FDG PET/CT may be considered for restaging of recurrent 
disease.
4.2.7 Suspected recurrence
• FDG PET/CT may be considered.
4.2.8 Surveillance
• FDG PET/CT is not recommended for routine follow-up.
4.2.9 Radiotherapy planning
• FDG PET/CT may be considered.
4.3 Hepatoblastoma
4.3.1 Screening
• FDG PET/CT is not recommended for screening at-risk 
populations.
4.3.2 Diagnosis
• FDG PET/CT is not recommended for diagnosis.
4.3.3 Staging
• FDG PET/CT may be considered for initial staging.[4]
4.3.4 Restaging/response post therapy
• FDG PET/CT may be considered.
4.3.5 Suspected recurrence
• FDG PET/CT may be considered.
4.3.6 Surveillance
• FDG PET/CT is not recommended for routine follow-up.
4.3.7 Radiotherapy planning
• FDG PET/CT may be considered.
4.4 Lymphomas
This topic is covered extensively in the adult context (see HL (2.6.1) 
and NHL (2.6.2)), and it is similar in the paediatric population.
4.4.1 Screening
• FDG PET/CT is not recommended for screening at risk 
populations.
4.4.2 Diagnosis
• FDG PET/CT may be considered for directing the surgeon to an 
appropriate biopsy site.
4.4.3 Staging
• PET/CT is recommended for routine staging. The baseline staging 
scan is also essential for accurate interpretation of scans for 
response assessment and restaging post therapy.
4.4.4 Early response assessment
• FDG PET/CT is recommended to determine early treatment 
response in lymphoma. Interim FDG PET/CT during mid-
therapy is prognostic of treatment response and survival in 
lymphoma.[3]
4.4.5 Restaging/response post theray
• FDG PET/CT at completion of therapy is recommended in 
lymphoma and is prognostic of treatment success and subsequent 
survival. It is the preferred restaging method of lymphoma 
(assessment should be made using Deauville criteria).[1,3]
4.4.6 Suspected recurrence
• FDG PET/CT is recommended in suspected recurrence of 
lymphoma.
4.4.7 Surveillance
• FDG PET/CT is not recommended for routine follow-up.
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4.4.8 Radiotherapy planning
• FDG PET/CT may be considered in radiotherapy treatment 
planning.
5. Neurology
5.1 Dementia and mild cognitive impairment (MCI)
5.1.1 18F-FDG
• FDG PET/CT is recommended in select cases of dementia where 
the diagnosis remains in doubt after clinical and structural imaging 
work-up.[1] FDG PET/CT should not be used as the only imaging 
measure. FDG PET/CT is particularly useful in distinguishing 
moderate to severe Alzheimer’s dementia (AD) from other 
neurodegenerative dementias (especially AD v. frontotemporal 
dementia).
• In patients with MCI (evaluated by a dementia specialist), FDG 
PET/CT may be considered if findings of a neurodegenerative 
pathology would affect management. An AD-like metabolic pattern 
on FDG PET in a patient with MCI is predictive of conversion to 
AD within several years.
• FDG PET/CT is not recommended in cases of cognitive decline 
due to suspected normal-pressure hydrocephalus, suspected 
Huntington’s disease, suspected brain iron accumulation, motor 
neuron disease or parkinsonian syndromes.
5.1.2 Amyloid agents
• Amyloid PET (e.g. 18F-florbetapir, 18F-florbetaben, etc.) is 
recommended in select cases, in the clinical situations below for 
individuals with all of the following characteristics: (i) a cognitive 
complaint with objectively confirmed impairment; (ii) AD as a 
possible diagnosis but diagnosis uncertain after comprehensive 
evaluation by a dementia expert; and (iii) knowledge of the 
presence or absence of AD pathology is expected to increase 
diagnostic certainty and alter management.
• Persistent or progressive unexplained MCI
• Patients satisfy core clinical criteria for possible AD (not 
probable AD) because of unclear clinical presentation – either an 
atypical clinical course or an aetiologically mixed presentation
• Progressive dementia and atypically early age of onset (≤65 years 
old).
• Amyloid PET is not recommended in the following clinical 
situations:
• Patients with core clinical criteria for probable AD with typical 
age of onset
• To determine dementia severity
• Based solely on a positive family history of dementia or presence 
of apolipoprotein E (APOE)ε4
• Cognitive complaint that is unconfirmed on clinical examination
• In lieu of genotyping for suspected autosomal mutation carriers
• In asymptomatic individuals
• Non-medical use (e.g. legal, insurance coverage or employment 
screening).
5.2 Movement disorders
• FDG PET/CT is not recommended in routine work-up of 
Parkinson’s disease (PD) or for differentiating PD from atypical 
parkinsonian syndromes (APS). While there is some evidence for 
the utility of FDG PET/CT in PD and APS, clinical guidelines do 
not yet endorse this indication as routine.
• In the investigation of movement disorders, FDG PET/CT may be 
considered in select clinical scenarios, to support or refute clinical 
impressions.[3] Referral of such cases should be by movement disorder 
specialists. These studies should only be performed by centres 
with sufficient experience in interpreting such studies. Visual and 
quantitative analysis (in comparison with a locally derived normal 
database) is recommended.
5.3 Seizure disorders
• FDG PET/CT is not recommended in routine work-up of epilepsy.
• FDG PET/CT may be considered in the presurgical work-
up of medically refractory focal epilepsy, in cases where 
MRI and ictal scalp electroencephalogram do not identify 
a clear epilepto genic focus or where these investigations 
are discordant or inconclusive.[4] Focal hypometabolism on 
interictal FDG PET can identify potential surgical candidates 
and assist in the decision to perform invasive intracranial 
recording. FDG PET/CT cannot be used to precisely identify 
surgical margins but assists in lateralisation and general 
localisation of epileptogenic foci. FDG PET appears to be 
predictive of surgical success in these patients.
5.4 Psychiatric conditions
• With the exception of the neurodegenerative dementias, FDG 
PET/CT is not recommended for psychiatric conditions per se.
6. Cardiology
6.1 Myocardial viability
• FDG PET/CT is recommended in select cases for patients with 
left ventricular dysfunction due to coronary artery disease who are 
eligible for coronary revascularisation and have resting myocardial 
perfusion defects, in order to differentiate viable (i.e. hibernation) 
from non-viable myocardium (i.e. scar),[1] the rationale being that 
if myocardial viability (hibernation or inducible ischaemia) is 
present, the patient has a great probability of beneﬁting clinically 
from revascularisation.[2-4] FDG PET is ideally used in conjunction 
with perfusion imaging (sestamibi/tetrofosmin SPECT or 
ammonia/rubidium PET).
7. Infection and inflammation
Clinical indications have not yet been developed. Based on EANM/
SNMMI Guideline for 18F-FDG use in Inflammation and Infection 
(2013).[1]
• FDG PET/CT is recommended in select cases for the investigation 
of:
• Sarcoidosis – for assessment of disease activity and distribution
• Peripheral bone osteomyelitis (non-postoperative, non-diabetic 
foot)
• Suspected spinal infection (spondylodiskitis or vertebral 
osteomyelitis, non-postoperative)
• Fever of unknown origin (FUO) including true FUO (defined 
according to the criteria of Durack and Street, postoperative 
fever and recurrent sepsis, immunodeficiency (both induced and 
acquired)-related FUO, neutropenic fever, and isolated acute-
phase inflammation markers (persistently raised C-reactive 
protein and/or erythrocyte sedimentation rate)[1,2]
• Metastatic infection and high-risk patients with bacteraemia
• Vasculitis – where conventional investigations are not helpful 
and treatment would be altered if confirmed
• For diagnosis, and possible determination of the extent and 
distribution of the disease activity
• To determine disease activity in confirmed medium- to large-
vessel arteritis where treatment would be altered if ongoing 
inflammatory disease is confirmed
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• To exclude underlying malignancy in patients with atypical 
presentations of vasculitis that may be on a paraneoplastic 
basis.
• FDG PET/CT may be considered in:
• Potentially infected liver and kidney cysts in polycystic 
disease
• Potentially infected intravascular devices, pacemakers and 
catheters (provided sufficient time has lapsed since surgery)
• AIDS-associated opportunistic infections, associated tumours 
and Castleman’s disease
• To assess metabolic activity in TB.
• FDG PET/CT is not indicated in the investigation of:
• Diabetic foot infections
• Joint prosthetic infections
• Vascular prosthetic infections
• Inflammatory bowel diseases
• Endocarditis
• FUO – prolonged (>3 weeks) hyperthermia (>38.3°C) with no 
specific aetiology identified despite extensive diagnostic work-
up.[3,4]
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